Catalogue Number: C4446-APE
| Manufacturer: | Apexbio |
| Molecular Formula: | C39H51N6O9 3I |
| Type: | Other Inhibitors |
| Shipping Condition: | Blue Ice |
| Storage Condition: | 2-8°C |
| Unit(s): | 10 mg, 25 mg, 5 mg |
Description: IC50: 0.3 +/- 0.02 µM for AChE; 3.9 +/- 0.2 µM for BuChE TAE-1 is an inhibitor of amyloid-β fibril formation and aggregation.Alzheimer's disease (AD), a progressive neurodegenerative disorder, is characterized by the cerebral accumulation of insoluble aggregates of amyloid-β peptides (Aβ). Although the precise mechanisms governing neuronal loss remains ambiguous, toxicity resulting from Aβ-activated pathways is evident.In vitro: In a previous study, the authors examined the effects of TAE-1 on differentiated human SH-SY5Y neuronal cells grown in tissue culture. Results showed that the stimulation of neuronal cellular process length and branching was noted. Moreover, the increased synaptophysin suggested that TAE-1 could stimulate synapse formation. Increased expression of MAP2 was also observed, indicating that TAE-1 promoted the differentiation of human neurons. In addition, targeted AChE inhibition was evaluated by electrochemical quantification of the enzymatic product, thiocholine, on unmodified gold screen-printed electrodes. It was found that at increasing TAE-1concentrations, there was a corresponding decrease in the AChE activity resulting in reduced amount of oxidizable thiocholine. The IC50 value was found to be 0.465 µM for TAE-1 [1].In vivo: Up to now, there is no animla in vivo data reported.Clinical trial: So far, no clinical study has been conducted.Reference:[1] Veloso AJ, Chow AM, Dhar D, Tang DW, Ganesh HV, Mikhaylichenko S, Brown IR, Kerman K.Biological activity of sym-triazines with acetylcholine-like substitutions as multitarget modulators of Alzheimer's disease. ACS Chem Neurosci. 2013 Jun 19;4(6):924-9.
Store at 2-8°C
Soluble in DMSO
O=C(OCC[N+](C)(C)C)C(C=C1)=CC=C1OC2=NC(OC3=CC=C(C(OCC[N+](C)(C)C)=O)C=C3)=NC(OC4=CC=C(C(OCC[N+](C)(C)C)=O)C=C4)=N2.[I-].[I-].[I-]